# Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer

> **NCT06575725** · PHASE2 · WITHDRAWN · sponsor: **City of Hope Medical Center**

## Conditions studied

- Advanced Colon Adenocarcinoma
- Advanced Colorectal Adenocarcinoma
- Advanced Rectal Adenocarcinoma
- Metastatic Colon Adenocarcinoma
- Metastatic Colorectal Adenocarcinoma
- Metastatic Rectal Adenocarcinoma
- Stage III Colon Cancer AJCC v8
- Stage III Colorectal Cancer AJCC v8
- Stage III Rectal Cancer AJCC v8
- Stage IV Colon Cancer AJCC v8
- Stage IV Colorectal Cancer AJCC v8
- Stage IV Rectal Cancer AJCC v8

## Interventions

- **BIOLOGICAL:** Balstilimab
- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **BIOLOGICAL:** Botensilimab
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Regorafenib

## Key facts

- **NCT ID:** NCT06575725
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-11-01
- **Primary completion:** 2027-01-28
- **Final completion:** 2027-01-28
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Abandoned 9/23/24
- **Last updated:** 2024-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06575725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06575725, "Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06575725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*